Xuelin (Steve) Wang
Lawyers
Filters
New Horizon Health HK$2.04 billion IPO
We advised New Horizon Health on its IPO and HKEX listing
Akeso HK$1.19 billion share placement
We advised the placing agent in the placement of new shares
Adagene $161 million IPO
We advised Adagene on its IPO and Nasdaq listing
Ocumension Therapeutics HK$793.8 million top-up placement of shares
We advised the placing agent in connection with the equity offering
Innovent Biologics HK$4.73 billion placement of shares
We advised the joint placing agents in connection with the equity offering
Gracell Biotechnologies $209 million IPO and Nasdaq listing
We advised the underwriters on the IPO of ADSs
Zhenro Properties $400 million high-yield notes offering
We advised Zhenro Properties on the Regulation S offering
Zhenro Properties $300 million high-yield notes offering
We advised the initial purchasers on the Regulation S senior notes offering
Antengene HK$2.79 billion IPO
Davis Polk advised Antengene Corporation Limited in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in reliance on Rule…
RemeGen HK$4 billion Hong Kong IPO
Davis Polk advised the underwriters in the initial public offering of RemeGen Co., Ltd. on the Hong Kong Stock Exchange and an international offering and listing in reliance on Rule 144A…